Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

By: Global Markets Direct
, Published: Dec-2016
, Product code: GMDHC8864IDB
Key Insights
    • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
    • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Companies mentioned in this product:

3-V Biosciences Inc 3SBio Inc 4SC AG AbbVie Inc Ability Pharmaceuticals SL ACEA Biosciences Inc Acetylon Pharmaceuticals Inc Adamed Sp z oo Adaptimmune Therapeutics Plc Advanced Cancer Therapeutics Advantagene Inc Advenchen Laboratories LLC Allist Shanghai Pharmaceutical Technology Co Ltd Almac Discovery Ltd Altimmune Inc Altor BioScience Corp Amgen Inc Andarix Pharmaceuticals Inc AndroScience Corp Apac Biotech Pvt Ltd APO-T BV Aptevo Therapeutics Inc Aptose Biosciences Inc Argos Therapeutics Inc Ariad Pharmaceuticals Inc ARMO Biosciences Inc Arog Pharmaceuticals Inc ArQule Inc Array BioPharma Inc Arrien Pharmaceuticals LLC Asana BioSciences LLC Astellas Pharma Inc Asterias Biotherapeutics Inc Astex Pharmaceuticals Inc AstraZeneca Plc ATLAB Pharma SAS Atreca Inc Aurigene Discovery Technologies Ltd AVEO Pharmaceuticals Inc Axelar AB Azaya Therapeutics Inc Basilea Pharmaceutica Ltd Batu Biologics Inc Bavarian Nordic A/S Bayer AG BeiGene Ltd BerGenBio AS Beta Pharma Inc Betta Pharmaceuticals Co Ltd BeyondSpring Pharmaceuticals Inc Bio-Path Holdings Inc Biocad BioCancell Ltd Biocon Ltd BioLineRx Ltd Bionovis SA Biothera Pharmaceutical Inc Blueprint Medicines Corp Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc CanBas Co Ltd Cantargia AB CASI Pharmaceuticals Inc CBT Pharmaceuticals Inc Celgene Corp CellAct Pharma GmbH Cellceutix Corp Celldex Therapeutics Inc Cellectar Biosciences Inc Cellmid Ltd Cellular Biomedicine Group Inc Chipscreen Biosciences Ltd Chugai Pharmaceutical Co Ltd Cielo Therapeutics Inc Cipla Ltd Cleave Biosciences Inc Coherus BioSciences Inc Corcept Therapeutics Inc Cornerstone Pharmaceuticals Inc Corvus Pharmaceuticals Inc Critical Outcome Technologies Inc CSPC Pharmaceutical Group Limited CTI BioPharma Corp CytImmune Sciences Inc CytomX Therapeutics Inc CytRx Corp Daiichi Sankyo Company Ltd DanDrit Biotech A/S DEKK-TEC Inc DelMar Pharmaceuticals Inc Denovo Biopharma LLC DiNonA Inc Domainex Ltd DormaTarg Inc Double Bond Pharmaceutical International AB Dr. Reddy's Laboratories Ltd Eagle Pharmaceuticals Inc EirGenix Inc Eisai Co Ltd Eleison Pharmaceuticals LLC Eli Lilly and Company Endocyte Inc EnGeneIC Ltd EntreChem SL Enumeral Biomedical Holdings Inc Eudendron Srl Evotec AG Exelixis Inc F. Hoffmann-La Roche Ltd FibroStatin SL Five Prime Therapeutics Inc Fujifilm Corp G&E Herbal Biotechnology Co Ltd Ganymed Pharmaceuticals AG Gene Techno Science Co Ltd Genelux Corp Genentech Inc Genmab A/S Genocea Biosciences Inc Genor BioPharma Co Ltd Genosco Inc Genzyme Corp Gilead Sciences Inc GlaxoSmithKline Plc Globeimmune Inc GlycaNova Norway AS Glycotope GmbH Golden Biotechnology Corp Gradalis Inc Grunenthal GmbH Halozyme Therapeutics Inc Hanmi Pharmaceuticals Co Ltd Heat Biologics Inc HEC Pharm Co Ltd Helix BioPharma Corp Hemispherx Biopharma Inc Heptares Therapeutics Ltd HitGen LTD Horizon Pharma Plc Hutchison MediPharma Ltd iCeutica Inc Ideaya Biosciences Inc Ignyta Inc Immune Design Corp Immune Pharmaceuticals Inc ImmunGene Inc Immunocore Ltd ImmunoGen Inc Immunome Inc Immunomedics Inc Incuron LLC Incyte Corp Infinity Pharmaceuticals Inc Inflection Biosciences Ltd Innovent Biologics Inc Inovio Pharmaceuticals Inc Intas Pharmaceuticals Ltd Invectys SA Inventiva IO Biotech ApS Io Therapeutics Inc Ionis Pharmaceuticals Inc JHL Biotech Inc Jiangsu Hansoh Pharmaceutical Co Ltd Jiangsu Hengrui Medicine Co Ltd Jiangsu Kanion Pharmaceutical Co Ltd Johnson & Johnson Juno Therapeutics Inc Kadmon Corp LLC Komipharm International Co Ltd Kura Oncology Inc Kyowa Hakko Kirin Co Ltd Lantern Pharma Inc Les Laboratoires Servier SAS Lion Biotechnologies Inc Loxo Oncology, Inc. Mabion SA MacroGenics Inc Mallinckrodt Plc Mebiopharm Co Ltd MedImmune LLC Medisyn Technologies Inc Merck & Co Inc Merck KGaA Merrimack Pharmaceuticals Inc Mersana Therapeutics Inc Microlin Bio, Inc. Millennium Pharmaceuticals Inc Mirati Therapeutics Inc Molecular Partners AG MolMed SpA Morphotek Inc Multimmune GmbH Mycenax Biotech Inc NanoCarrier Co Ltd Natco Pharma Ltd Nektar Therapeutics Nemucore Medical Innovations Inc NeoPharm Co Ltd Netris Pharma SAS Neumedicines Inc NewLink Genetics Corp Northwest Biotherapeutics Inc Novartis AG NuCana BioMed Ltd Omnitura Therapeutics Inc Oncobiologics Inc Oncogenex Pharmaceuticals Inc Oncolys BioPharma Inc Oncolytics Biotech Inc OncoMed Pharmaceuticals Inc Ono Pharmaceutical Co Ltd Onxeo SA Optimum Therapeutics LLC Oribase Pharma Oscotec Inc OSE Immunotherapeutics Oxford BioTherapeutics Ltd Paranta Biosciences Ltd Pfizer Inc Pharma Mar SA Philogen SpA Phosplatin Therapeutics LLC Pique Therapeutics Plexxikon Inc Polaris Pharmaceuticals Inc ProNAi Therapeutics Inc Provectus Biopharmaceuticals Inc PsiOxus Therapeutics Ltd Puma Biotechnology Inc Purdue Pharma LP Qu Biologics Inc Reata Pharmaceuticals Inc Recombio SL Rexahn Pharmaceuticals Inc Rgenix Inc Richter Gedeon Nyrt Samyang Holdings Corp Sanofi Sapvax Scancell Holdings Plc SciClone Pharmaceuticals Inc ScinoPharm Taiwan Ltd Shanghai Fosun Pharmaceutical (Group) Co Ltd Shanghai Henlius Biotech Co Ltd Shanghai Pharmaceutical Co Ltd Shionogi & Co Ltd Sigma-Tau SpA SignPath Pharma Inc Sorrento Therapeutics Inc Sotio as
Table of Contents
Table of Contents
Table of Contents 2
Introduction 14
Non-Small Cell Lung Cancer Overview 15
Therapeutics Development 16
Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 18
Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 43
Non-Small Cell Lung Cancer - Pipeline Products Glance 46
Non-Small Cell Lung Cancer - Products under Development by Companies 50
Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 92
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 96
Non-Small Cell Lung Cancer - Therapeutics Assessment 387
Drug Profiles 487
Non-Small Cell Lung Cancer - Dormant Projects 2104
Non-Small Cell Lung Cancer - Discontinued Products 2139
Non-Small Cell Lung Cancer - Product Development Milestones 2153
Appendix 2169
Tables and Figures
List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016 82
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016 83
Number of Products under Development by Companies, H2 2016 85
Number of Products under Development by Companies, H2 2016 (Contd..1) 86
Number of Products under Development by Companies, H2 2016 (Contd..2) 87
Number of Products under Development by Companies, H2 2016 (Contd..3) 88
Number of Products under Development by Companies, H2 2016 (Contd..4) 89
Number of Products under Development by Companies, H2 2016 (Contd..5) 90
Number of Products under Development by Companies, H2 2016 (Contd..6) 91
Number of Products under Development by Companies, H2 2016 (Contd..7) 92
Number of Products under Development by Companies, H2 2016 (Contd..8) 93
Number of Products under Development by Companies, H2 2016 (Contd..9) 94
Number of Products under Development by Companies, H2 2016 (Contd..10) 95
Number of Products under Development by Companies, H2 2016 (Contd..11) 96
Number of Products under Development by Companies, H2 2016 (Contd..12) 97
Number of Products under Development by Companies, H2 2016 (Contd..13) 98
Number of Products under Development by Companies, H2 2016 (Contd..14) 99
Number of Products under Development by Companies, H2 2016 (Contd..15) 100
Number of Products under Development by Companies, H2 2016 (Contd..16) 101
Number of Products under Development by Companies, H2 2016 (Contd..17) 102
Number of Products under Development by Companies, H2 2016 (Contd..18) 103
Number of Products under Development by Companies, H2 2016 (Contd..19) 104
Number of Products under Development by Companies, H2 2016 (Contd..20) 105
Number of Products under Development by Companies, H2 2016 (Contd..21) 106
Number of Products under Development by Companies, H2 2016 (Contd..22) 107
Number of Products under Development by Companies, H2 2016 (Contd..23) 108
Number of Products under Investigation by Universities/Institutes, H2 2016 109
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 110
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 111
Comparative Analysis by Late Stage Development, H2 2016 112
Comparative Analysis by Clinical Stage Development, H2 2016 113
Comparative Analysis by Early Stage Development, H2 2016 114
Comparative Analysis by Unknown Stage Development, H2 2016 115
Products under Development by Companies, H2 2016 116
Products under Development by Companies, H2 2016 (Contd..1) 117
Products under Development by Companies, H2 2016 (Contd..2) 118
Products under Development by Companies, H2 2016 (Contd..3) 119
Products under Development by Companies, H2 2016 (Contd..4) 120
Products under Development by Companies, H2 2016 (Contd..5) 121
Products under Development by Companies, H2 2016 (Contd..6) 122
Products under Development by Companies, H2 2016 (Contd..7) 123
Products under Development by Companies, H2 2016 (Contd..8) 124
Products under Development by Companies, H2 2016 (Contd..9) 125
Products under Development by Companies, H2 2016 (Contd..10) 126
Products under Development by Companies, H2 2016 (Contd..11) 127
Products under Development by Companies, H2 2016 (Contd..12) 128
Products under Development by Companies, H2 2016 (Contd..13) 129
Products under Development by Companies, H2 2016 (Contd..14) 130
Products under Development by Companies, H2 2016 (Contd..15) 131
Products under Development by Companies, H2 2016 (Contd..16) 132
Products under Development by Companies, H2 2016 (Contd..17) 133
Products under Development by Companies, H2 2016 (Contd..18) 134
Products under Development by Companies, H2 2016 (Contd..19) 135
Products under Development by Companies, H2 2016 (Contd..20) 136
Products under Development by Companies, H2 2016 (Contd..21) 137
Products under Development by Companies, H2 2016 (Contd..22) 138
Products under Development by Companies, H2 2016 (Contd..23) 139
Products under Development by Companies, H2 2016 (Contd..24) 140
Products under Development by Companies, H2 2016 (Contd..25) 141
Products under Development by Companies, H2 2016 (Contd..26) 142
Products under Development by Companies, H2 2016 (Contd..27) 143
Products under Development by Companies, H2 2016 (Contd..28) 144
Products under Development by Companies, H2 2016 (Contd..29) 145
Products under Development by Companies, H2 2016 (Contd..30) 146
Products under Development by Companies, H2 2016 (Contd..31) 147
Products under Development by Companies, H2 2016 (Contd..32) 148
Products under Development by Companies, H2 2016 (Contd..33) 149
Products under Development by Companies, H2 2016 (Contd..34) 150
Products under Development by Companies, H2 2016 (Contd..35) 151
Products under Development by Companies, H2 2016 (Contd..36) 152
Products under Development by Companies, H2 2016 (Contd..37) 153
Products under Development by Companies, H2 2016 (Contd..38) 154
Products under Development by Companies, H2 2016 (Contd..39) 155
Products under Development by Companies, H2 2016 (Contd..40) 156
Products under Development by Companies, H2 2016 (Contd..41) 157
Products under Investigation by Universities/Institutes, H2 2016 158
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 159
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 160
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 161
Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 162
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H2 2016 163
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2016 164
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2016 165
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016 166
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H2 2016 167
Non-Small Cell Lung Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 168
Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H2 2016 169
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 170
Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 171
Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2016 172
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 173
Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2016 174
Non-Small Cell Lung Cancer - Pipeline by Almac Discovery Ltd, H2 2016 175
Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H2 2016 176
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H2 2016 177
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H2 2016 178
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 179
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H2 2016 180
Non-Small Cell Lung Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 181
Non-Small Cell Lung Cancer - Pipeline by APO-T BV, H2 2016 182
Non-Small Cell Lung Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 183
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 184
Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H2 2016 185
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 186
Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 187
Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016 188
Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H2 2016 189
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H2 2016 190
Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 191
Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H2 2016 192
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2016 193
Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016 194
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 195
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2016 196
Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 197
Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H2 2016 198
Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 199
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 200
Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H2 2016 201
Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 202
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 203
Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H2 2016 204
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 205
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2016 206
Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2016 207
Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H2 2016 208
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2016 209
Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 210
Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 211
Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 212
Non-Small Cell Lung Cancer - Pipeline by Biocad, H2 2016 213
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2016 214
Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H2 2016 215
Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2016 216
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2016 217
Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016 218
Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H2 2016 219
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 220
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H2 2016 221
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 222
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 223
Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H2 2016 224
Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H2 2016 225
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 226
Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016 227
Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H2 2016 228
Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2016 229
Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corp, H2 2016 230
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 231
Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 232
Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H2 2016 233
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 234
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 235
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 236
Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016 237
Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd, H2 2016 238
Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H2 2016 239
Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 240
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 241
Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 242
Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 243
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 244
Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 245
Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp, H2 2016 246
Non-Small Cell Lung Cancer - Pipeline by CytImmune Sciences Inc, H2 2016 247
Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 248
Non-Small Cell Lung Cancer - Pipeline by CytRx Corp, H2 2016 249
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 250
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2016 251
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H2 2016 252
Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 253
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H2 2016 254
Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc, H2 2016 255
Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H2 2016 256
Non-Small Cell Lung Cancer - Pipeline by DormaTarg Inc, H2 2016 257
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 258
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 259
Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals Inc, H2 2016 260
Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc, H2 2016 261
Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H2 2016 262
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016 263
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2016 264
Non-Small Cell Lung Cancer - Pipeline by Endocyte Inc, H2 2016 265
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2016 266
Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H2 2016 267
Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H2 2016 268
Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H2 2016 269
Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H2 2016 270
Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H2 2016 271
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 272
Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H2 2016 273
Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2016 274
Non-Small Cell Lung Cancer - Pipeline by Fujifilm Corp, H2 2016 275
Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2016 276
Non-Small Cell Lung Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016 277
Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 278
Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H2 2016 279
Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H2 2016 280
Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2016 281
Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H2 2016 282
Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 283
Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H2 2016 284
Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2016 285
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H2 2016 286
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 287
Non-Small Cell Lung Cancer - Pipeline by Globeimmune Inc, H2 2016 288
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2016 289
Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2016 290
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H2 2016 291
Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H2 2016 292
Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H2 2016 293
Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016 294
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 295
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H2 2016 296
Non-Small Cell Lung Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016 297
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H2 2016 298
Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016 299
Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H2 2016 300
Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H2 2016 301
Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2016 302
Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016 303
Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H2 2016 304
Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016 305
Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H2 2016 306
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H2 2016 307
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 308
Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H2 2016 309
Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H2 2016 310
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H2 2016 311

List of Figures
Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016 82
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016 83
Number of Products under Development by Companies, H2 2016 84
Number of Products under Investigation by Universities/Institutes, H2 2016 109
Comparative Analysis by Late Stage Development, H2 2016 112
Comparative Analysis by Clinical Stage Development, H2 2016 113
Comparative Analysis by Early Stage Products, H2 2016 114
Assessment by Monotherapy Products, H2 2016 453
Assessment by Combination Products, H2 2016 454
Number of Products by Top 10 Targets, H2 2016 455
Number of Products by Stage and Top 10 Targets, H2 2016 455
Number of Products by Top 10 Mechanism of Actions, H2 2016 504
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 504
Number of Products by Top 10 Routes of Administration, H2 2016 549
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 549
Number of Products by Top 10 Molecule Types, H2 2016 551
Number of Products by Stage and Top 10 Molecule Types, H2 2016 551
Sample Pages

Request Sample Pages

Non-Small Cell Lung Cancer - Pipeline Review, H2 2016
By: Global Markets Direct
Published: Dec 2016
Contact Details


Download Brochure

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer – Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 45, 178, 148, 1, 16, 156, 17 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 7, 37 and 7 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Synopsis

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Reasons To Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Quick Overview

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer – Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

More information about Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

For more information on this report or to speak to one of our experts

Call us on +44(0)20 7936 6830 or Email us

mail

For more information
on this report or to speak to one of our experts

Email us or call us on
+44(0)20 7936 6830

Purchase

Site License - This allows anybody within a business at the same site to view the report.

Single-user - This allows only one person to view the report.

Enterprise License -  This allows anybody globally within the organisation to view the report.

Preview Report

For a free preview of this report please complete our simple form.

Request
mail

Read our latest
Industry Insights Blog
and stay informed